CADTH

pan-Canadian Oncology Drug Review Stakeholder Feedback on a pCODR Expert Review Committee Initial Recommendation (Provincial Advisory Group [PAG])

Larotrectinib (Vitrakvi) for NTRK+ solid tumours

October 31, 2019

3 Feedback on pERC Initial Recommendation

Name of the Drug and Indication(s):	Larotrectinib for NTRK Locally Advanced or Metastatic Solid Tumours
Eligible Stakeholder Role in Review (Submitter and/or Manufacturer, Patient Organization Providing Feedback Contact Person*:	PAG

**The pCODR program may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by pCODR.*

3.1 Comments on the Initial Recommendation

a) Please indicate if the eligible stakeholder agrees, agrees in part, or disagrees with the Initial Recommendation:

☒ agrees ☐ agrees in part ☐ disagree

PAG agrees with the Initial Recommendation and supports conversion to Final Recommendation; provided the following feedback is addressed.

b) Please provide editorial feedback on the Initial Recommendation to aid in clarity. Is the Initial Recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity
			The response to the PAG question on optimal sequencing of larotectinib with other treatment options is not clear: 1. It is stated that "pERC agreed that these patients will have no satisfactory treatment options". However, it is not clear if these patients would be eligible upfront and in the first-line setting or only after failure of chemotherapy or other systemic therapy options.

			2. PAG noted that the existing terminology of "satisfactory treatment options" is very subjective and larotrectinib's place in therapy would be at the discretion of the oncologist. It would be useful to align the wording in the Appendix with wording in the Recommendation to "(This recommendation pertains only to adult and pediatric patients with salivary gland tumours, adult or pediatric patients with soft tissue sarcoma [STS], and pediatric patients with cellular congenital mesoblastic nephroma or infantile fibrosarcoma), without a known acquired resistance mutation, **that are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory treatment options**". PAG noted a treatment algorithm would be helpful to clarify larotrectinib's place in therapy.
	pERC Recommendation		Suggest changing bracketed section "(This recommendation pertains only to adult and pediatric patients with salivary gland tumours, adult or pediatric patients with soft tissue sarcoma [STS], and pediatric patients with cellular congenital mesoblastic nephroma or infantile fibrosarcoma)" into a sentence Suggest changing "without a known acquired resistance mutation" to "'patient/disease/tumor must not have co-existing oncogenic driver mutation" assuming this is the intent of the statement.
	Potential Next Steps for Stakeholders		PAG noted it would be important to highlight that testing for NTRK gene fusion status should be reserved for the patient population recommended for reimbursement by pERC.

3.2 Comments Related to Eligible Stakeholder Provided Information

Notwithstanding the feedback provided in part a) above, please indicate if the Stakeholder would support this Initial Recommendation proceeding to Final pERC Recommendation ("early conversion"), which would occur two (2) Business Days after the end of the feedback deadline date.

☒	Support conversion to Final Recommendation. Recommendation does not require reconsideration by pERC.	☐	Do not support conversion to Final Recommendation. Recommendation should be reconsidered by pERC.

If the eligible stakeholder does not support conversion to a Final Recommendation, please provide feedback on any issues not adequately addressed in the Initial Recommendation based on any information provided by the Stakeholder in the submission or as additional information during the review.

Please note that new evidence will be not considered at this part of the review process, however, it may be eligible for a Resubmission. If you are unclear as to whether the information you are providing is eligible for a Resubmission, please contact the pCODR program.

Additionally, if the eligible stakeholder supports early conversion to a Final Recommendation; however, the stakeholder has included substantive comments that requires further interpretation of the evidence, the criteria for early conversion will be deemed to have not been met and the Initial Recommendation will be returned to pERC for further deliberation and reconsideration at the next possible pERC meeting.

Page Number	Section Title	Paragraph, Line Number	Comments related to Stakeholder Information